Literature DB >> 16916825

Psoriasis and its management.

Catherine H Smith1, J N W N Barker.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16916825      PMCID： PMC1550454          DOI： 10.1136/bmj.333.7564.380

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  27 in total

Review 1.  A systematic review of treatments for severe psoriasis.

Authors:  C E Griffiths; C M Clark; R J Chalmers; A Li Wan Po; H C Williams
Journal:  Health Technol Assess       Date:  2000       Impact factor: 4.014

Review 2.  Recent insights into the immunopathogenesis of psoriasis provide new therapeutic opportunities.

Authors:  Brian J Nickoloff; Frank O Nestle
Journal:  J Clin Invest       Date:  2004-06       Impact factor: 14.808

Review 3.  Psychologic factors in psoriasis: consequences, mechanisms, and interventions.

Authors:  Dónal G Fortune; Helen L Richards; Christopher E M Griffiths
Journal:  Dermatol Clin       Date:  2005-10       Impact factor: 3.478

4.  Obesity, smoking, and psoriasis.

Authors:  Mark Lebwhol; Jeffery P Callen
Journal:  JAMA       Date:  2006-01-11       Impact factor: 56.272

5.  Cancer risk in a population-based cohort of patients hospitalized for psoriasis in Sweden.

Authors:  P Boffetta; G Gridley; B Lindelöf
Journal:  J Invest Dermatol       Date:  2001-12       Impact factor: 8.551

6.  Evaluation of a general practitioner with special interest service for dermatology: randomised controlled trial.

Authors:  Chris Salisbury; Alison Noble; Sue Horrocks; Zoe Crosby; Viv Harrison; Joanna Coast; David de Berker; Tim Peters
Journal:  BMJ       Date:  2005-12-06

7.  Replacement of routine liver biopsy by procollagen III aminopeptide for monitoring patients with psoriasis receiving long-term methotrexate: a multicentre audit and health economic analysis.

Authors:  R J G Chalmers; B Kirby; A Smith; P Burrows; R Little; M Horan; J M Hextall; C H Smith; M Klaber; S Rogers
Journal:  Br J Dermatol       Date:  2005-03       Impact factor: 9.302

Review 8.  Adverse effects of topical glucocorticosteroids.

Authors:  Ulrich R Hengge; Thomas Ruzicka; Robert A Schwartz; Michael J Cork
Journal:  J Am Acad Dermatol       Date:  2006-01       Impact factor: 11.527

Review 9.  Quality of life in patients with psoriasis: a systematic literature review.

Authors:  John de Korte; Mirjam A Sprangers; Femke M Mombers; Jan D Bos
Journal:  J Investig Dermatol Symp Proc       Date:  2004-03

10.  Spontaneous development of psoriasis in a new animal model shows an essential role for resident T cells and tumor necrosis factor-alpha.

Authors:  Onur Boyman; Hans Peter Hefti; Curdin Conrad; Brian J Nickoloff; Mark Suter; Frank O Nestle
Journal:  J Exp Med       Date:  2004-02-23       Impact factor: 14.307
View more
  19 in total

1.  MicroRNA-520a suppresses the proliferation and mitosis of HaCaT cells by inactivating protein kinase B.

Authors:  Rui Wang; Zigang Zhao; Liqiang Zheng; Xiaojing Xing; Wei Ba; Junfen Zhang; Min Huang; Wenwei Zhu; Bing Liu; Xianfu Meng; Jia Bai; Chengxin Li; Hengjin Li
Journal:  Exp Ther Med       Date:  2017-10-17       Impact factor: 2.447

Review 2.  Hepatotoxicity related to antirheumatic drugs.

Authors:  Guruprasad P Aithal
Journal:  Nat Rev Rheumatol       Date:  2011-01-25       Impact factor: 20.543

3.  Re-evaluation of the diagnosis of porphyria cutanea tarda in Admiral Sir Francis Beaufort.

Authors:  T J Peters; N J Levell
Journal:  JRSM Short Rep       Date:  2010-06-30

Review 4.  The Inflammatory Response in Psoriasis: a Comprehensive Review.

Authors:  Yaxiong Deng; Christopher Chang; Qianjin Lu
Journal:  Clin Rev Allergy Immunol       Date:  2016-06       Impact factor: 8.667

5.  Sequence variants in the genes for the interleukin-23 receptor (IL23R) and its ligand (IL12B) confer protection against psoriasis.

Authors:  Francesca Capon; Paola Di Meglio; Joanna Szaub; Natalie J Prescott; Christina Dunster; Laura Baumber; Kirsten Timms; Alexander Gutin; Victor Abkevic; A David Burden; Jerry Lanchbury; Jonathan N Barker; Richard C Trembath; Frank O Nestle
Journal:  Hum Genet       Date:  2007-06-22       Impact factor: 4.132

6.  Balneotherapy in Psoriasis Rehabilitation.

Authors:  Iván Péter; Anna Jagicza; Zénó Ajtay; Imre Boncz; István Kiss; Katalin Szendi; Péter Kustán; Balázs Németh
Journal:  In Vivo       Date:  2017 Nov-Dec       Impact factor: 2.155

7.  A cost-utility analysis of etanercept for the treatment of moderate-to-severe psoriasis in Italy.

Authors:  Giorgio L Colombo; Sergio Di Matteo; Ketty Peris; Maria Concetta Fargnoli; Maria Esposito; Annamaria Mazzotta; Sergio Chimenti
Journal:  Clinicoecon Outcomes Res       Date:  2009-10-15

8.  Implementation of the PsoWell™ Model for the Management of People with Complex Psoriasis.

Authors:  Rachael M Hewitt; Rachael Pattinson; Lis Cordingley; Christopher E M Griffiths; C. Elise Kleyn; Helen McAteer; Julia Schofield; Chris Bundy
Journal:  Acta Derm Venereol       Date:  2021-04-29       Impact factor: 3.875

9.  Clinical, Quality of Life, Patient Adherence, and Safety Outcomes of Short-Course (12 Weeks) Treatment with Cyclosporine in Patients with Severe Psoriasis (the Practice Study).

Authors:  Sandra Swimberghe; Pierre-Dominique Ghislain; Evis Daci; Katrien Allewaert; Kris Denhaerynck; Christine Hermans; Christy Pacheco; Stefaan Vancayzeele; Karen Macdonald; Ivo Abraham
Journal:  Ann Dermatol       Date:  2013-02-14       Impact factor: 1.444

Review 10.  Oral fumaric acid esters for psoriasis.

Authors:  Ausama Atwan; John R Ingram; Rachel Abbott; Mark J Kelson; Timothy Pickles; Andrea Bauer; Vincent Piguet
Journal:  Cochrane Database Syst Rev       Date:  2015-08-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.